RDNT RadNet Inc.

RadNet, Inc. to Present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference March 17th, 2025

RadNet, Inc. to Present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference March 17th, 2025

LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Executive Officer, will be presenting virtually at the 35th Oppenheimer Healthcare MedTech & Services Conference on Monday, March 17, 2025 at 12:40 p.m. Eastern Time.

A live webcast of RadNet's presentation can be accessed through the following link,

and is available for replay viewing.

About RadNet, Inc.

RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 398 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit more information, visit .

Contact:

RadNet, Inc.

Mark Stolper, Executive Vice President and Chief Financial Officer

310-445-2800



EN
13/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RadNet Inc.

 PRESS RELEASE

RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Dete...

RadNet, Inc. to Acquire iCAD, Inc. to Accelerate AI-Powered Early Detection and Diagnosis of Breast Cancer The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancerThe transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countriesWith iCAD’s seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate RadNet’s growth and lea...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: April 12, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

RadNet, Inc. to Present at the 35th Annual Oppenheimer Healthcare MedT...

RadNet, Inc. to Present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference March 17th, 2025 LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Executive Officer, will be presenting virtually at the 35th Oppenheimer Healthcare MedTech & Services Conference on Monday, March 17, 2025 at 12:40 p.m. Eastern Time. A l...

Radnet Inc: 1 director

A director at Radnet Inc sold 25,000 shares at 50.840USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch